Addithive Company Review · October 3, 2026
What changed
BICO reported Q2 2026 organic growth of 7.3% and a 59.3% gross margin while continuing to operate CELLINK bioprinting and 3D cell-culture platforms. The key signal is operating recovery, not a discrete bioprinting breakout.
Addithive read-through
The review separates demonstrated AM capability from financial materiality. Where a company has a concrete 2026 manufacturing or technology change, that is highlighted; where it does not, the absence of a new AM catalyst is recorded explicitly.
What to watch next
- Qualified customer adoption and repeat production.
- Capacity utilization and accepted-part throughput.
- New material/process approvals.
- Any disclosure that makes AM exposure financially measurable.
Primary sources
Research mapping only. This is not investment advice.